Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells

Ma,Li  Shan; Yan,Qi; Huang,Yongfang; Zhao,Wenxia; Zhu,Yu

doi:10.3892/ol.2015.3033

Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells

Authors:
- Li Shan Ma
- Qi Yan
- Yongfang Huang
- Wenxia Zhao
- Yu Zhu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, P.R. China, Department of Obstetrics and Gynecology, Jiangwan Hospital, Shanghai 200434, P.R. China
Published online on: March 12, 2015 https://doi.org/10.3892/ol.2015.3033
Pages: 2211-2217

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the current study was to investigate the suppressive effects of pSilencer T7‑human epidermal growth factor receptor 2 (HER2)‑short hairpin RNA (shRNA) recombinant plasmids on human SKOV3 ovarian cancer cell growth and sensitivity to carboplatin (CBP). Three different pairs of shRNAs (shRNAa, shRNAb and shRNAc), targeting the HER2 gene, were selected and transfected into human SKOV3 cells, respectively. The expression levels of HER2 were then detected by immunohistochemical (IHC), semi‑quantitative reverse transcription‑polymerase chain reaction and western blot analyses. In addition, cell cycle and cell growth were investigated using cell counting kit‑8 (CCK‑8). The results of the IHC and western blot analyses revealed that shRNAb significantly inhibited HER2 protein expression in SKOV3 cells. shRNAb exhibited an improved effect on HER2 expression compared with shRNAa (P<0.01), while shRNAc did not affect HER2 expression. Nontransfected and nonspecific shRNA groups were used as the negative controls. Knockdown of HER2 expression by shRNA was initiated at 24 h following transfection, achieving an optimum effect at 48 h and lasting for at least 72 h after the treatment. The CCK‑8 cell growth assay indicated that the knockdown of HER2 expression in the SKOV3 cell line resulted in significant growth suppression and cell cycle arrest. In addition, inhibition of HER2 significantly increased SKOV3 cell sensitivity to CBP treatment. In conclusion, pSilencer T7‑HER2‑shRNA significantly inhibited HER2 expression in human ovarian cancer cells in vitro and induced chemotherapeutic sensitivity to CBP.

View Figures

View References

1	Gentry-Maharaj A and Menon U: Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol. 26:243–256. 2012. View Article : Google Scholar : PubMed/NCBI
2	Klint A, Tryggvadóttir L, Bray F, et al: Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 49:632–643. 2010. View Article : Google Scholar : PubMed/NCBI
3	Permuth-Wey J and Sellers TA: Epidemiology of ovarian cancer. Methods Mol Biol. 472:413–437. 2009. View Article : Google Scholar : PubMed/NCBI
4	Zahedi P, Yoganathan R, Piquette-Miller M and Allen C: Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opin Drug Deliv. 9:567–583. 2012. View Article : Google Scholar : PubMed/NCBI
5	Shih IeM and Davidson B: Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol. 5:1641–1657. 2009. View Article : Google Scholar : PubMed/NCBI
6	Bulun SE: Uterine fibroids. N Engl J Med. 369:1344–1355. 2013. View Article : Google Scholar : PubMed/NCBI
7	Groenen LC, Nice EC and Burgess AW: Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors. 11:235–257. 1994. View Article : Google Scholar : PubMed/NCBI
8	Lemke G: Neuregulins in development. Mol Cell Neurosci. 7:247–262. 1996. View Article : Google Scholar : PubMed/NCBI
9	Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:4087–4091. 1990.PubMed/NCBI
10	Berchuck A, Rodriguez G, Kinney RB, et al: Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 164:15–21. 1991. View Article : Google Scholar : PubMed/NCBI
11	Tandon AK, Clark GM, Chamness GC, et al: HER-2/neu oncogeneprotein and prognosis in breast cancer. J Clin Oncol. 7:1120–1128. 1989.PubMed/NCBI
12	Meden H and Kuhn W: Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol. 71:173–179. 1997. View Article : Google Scholar : PubMed/NCBI
13	Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation ofrelapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
14	Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in humanbreast and ovarian cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
15	Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. In: Proc Natl Acad Sci USA. 89. pp. 4285–4289. 1992; View Article : Google Scholar : PubMed/NCBI
16	Verma S, Miles D, Gianni L, et al: EMILIA Study Group: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 367:1783–1791. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wu Y, Zhang Y, Wang M, et al: Downregulation of HER3 by a novel antisenseoligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther. 12:427–437. 2013. View Article : Google Scholar : PubMed/NCBI
18	Tai W, Mahato R and Cheng K: The role of HER2 in cancertherapy and targeted drug delivery. J Control Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ferracin M, Bassi C, Pedriali M, et al: miR-125b targetserythropoietin and itsreceptor and their expression correlates with metastaticpotential and ERBB2/HER2 expression. Mol Cancer. 12:1302013. View Article : Google Scholar : PubMed/NCBI
20	Corsi F, Fiandra L, De Palma C, et al: HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice. ACS Nano. 5:6383–6393. 2011. View Article : Google Scholar : PubMed/NCBI
21	Rho O, Kim DJ, Kiguchi K and Digiovanni J: Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog. 50:264–279. 2011. View Article : Google Scholar : PubMed/NCBI
22	Campone M, Noël B, Couriaud C, et al: c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol Cancer. 10:1102011. View Article : Google Scholar : PubMed/NCBI
23	Maillard PV, Ciaudo C, Marchais A, et al: Antiviral RNA interference in mammalian cells. Science. 342:235–238. 2013. View Article : Google Scholar : PubMed/NCBI
24	Mutch DG and Prat J: 2014 FIGO staging forovarian, fallopiantube and peritoneal cancer. Gynecol Oncol. 133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitativePCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	World Health Organization, . GLOBOCAN 2012: Estimated Cancer Incidence and Mortality Worldwide in 2012. http://globocan.iarc.frDecember 12–2013
27	Jemal A, Tiwari RC, Murray T, et al: American Cancer Society: Cancerstatistics, 2004. CA Cancer J Clin. 54:8–29. 2004. View Article : Google Scholar : PubMed/NCBI
28	Buys SS, Partridge E, Black A, et al: PLCO Project Team: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
29	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
30	Colombo N, Peiretti M, Parma G, et al: ESMO Guidelines Working Group: Newlydiagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines fordiagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5): S23–S30. 2010. View Article : Google Scholar
31	du Bois A, Lück HJ, Meier W, et al: Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as ﬁrst-line treatment of ovarian cancer. J Natl Cancer Inst. 95:1320–1329. 2003. View Article : Google Scholar : PubMed/NCBI
32	Levanon K, Crum C and Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI
33	Steffensen KD, Waldstrøm M, Jeppesen U, et al: The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer. 17:798–807. 2007. View Article : Google Scholar : PubMed/NCBI
34	Colombo PE, Fabbro M, Theillet C, et al: Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar : PubMed/NCBI
35	Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:4087–4091. 1990.PubMed/NCBI
36	Chao WR, Lee MY, Lin WL, et al: HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer. Hum Pathol. 45:810–816. 2014. View Article : Google Scholar : PubMed/NCBI
37	Shawver LK, Slamon D and Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 1:117–123. 2002. View Article : Google Scholar : PubMed/NCBI
38	Rao DD, Vorhies JS, Senzer N and Nemunaitis J: siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
39	Faltus T, Yuan J, Zimmer B, et al: Silencing of the HER2/neu gene by siRNA inhibitsproliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia. 6:786–795. 2004. View Article : Google Scholar : PubMed/NCBI